Go Backs
HomeCategoriesStatesCheck Your Home
Go Backs

Track product recalls and safety alerts from CPSC, FDA, NHTSA, and USDA. Stay informed and keep your family safe.

Browse

  • Categories
  • States
  • Check Your Home
  • Risk Levels

Agencies

  • CPSC
  • FDA Food
  • FDA Drug
  • FDA Device
  • FDA Veterinary
  • NHTSA
  • USDA

Company

  • About
  • FAQ
  • Contact
  • Terms of Service
  • Privacy Policy

Recall data is sourced from official U.S. government agencies (CPSC, FDA, NHTSA, USDA) and processed using AI to improve readability. This site is not affiliated with or endorsed by any government agency. Always refer to the original agency notice for authoritative information.

© 2026 Go Backs. All rights reserved.

Low RiskFDA Drug
Medications & Supplements/Over-the-Counter

SUN PHARMACEUTICAL INDUSTRIES INC: Loratadine-D and AllerClear D-24 hr Recalled for Failed Moisture Limits

Agency Publication Date: October 26, 2021
Share:
Sign in to monitor this recall

Summary

SUN PHARMACEUTICAL INDUSTRIES INC has recalled 69,336 units of Loratadine-D Extended-Release Tablets and AllerClear D-24 hr (loratadine and pseudoephedrine sulfate). The recall was initiated because the products failed moisture limit testing during stability checks. While no injuries have been reported, consumers should contact their healthcare provider or pharmacist regarding the use of these allergy and congestion medications. These products were distributed nationwide in the United States in 10-count and 15-count blister packs.

Risk

The tablets failed to meet moisture level standards, which can affect the stability and effectiveness of the medication over time. This may result in the drug not performing as expected for treating allergy symptoms and nasal congestion.

What You Should Do

  1. Check your medicine cabinet for Loratadine-D Extended-Release Tablets (10mg/240mg) in 10-count blister packs with NDC 0904-5833-15 and Lot AC14635 (Exp. 12/2022).
  2. Check for AllerClear D-24 hr (10mg/240mg) in 15-count blister packs with NDC 63981-724-15 and Lot AC09723 (Exp. 11/2022).
  3. If you have an affected product, contact your healthcare provider or pharmacist for guidance on alternative treatments and to determine if you should continue use.
  4. Return any unused blister packs to the pharmacy or place of purchase for a full refund.
  5. Contact SUN PHARMACEUTICAL INDUSTRIES INC at their Princeton, NJ office or through the distributor listed on the packaging for further instructions regarding this voluntary recall.
  6. For additional questions, contact the FDA Consumer Complaint hotline at 1-888-723-3332 (1-888-SAFEFDA) or visit www.fda.gov/safety/recalls.

Your Remedy Options

💰Full Refund

Drug recall refund

How to: Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund

Affected Products

Product: Loratadine-D Extended-Release Tablets (10-count blister packs)
Model:
NDC 0904-5833-15
Recall #: D-0068-2022
Lot Numbers:
AC14635 (Exp. Date 12/2022)
Date Ranges: 12/2022
Product: AllerClear D-24 hr (15-count blister packs)
Model:
NDC 63981-724-15
Recall #: D-0069-2022
Lot Numbers:
AC09723 (Exp. Date 11/2022)
Date Ranges: 11/2022

Additional Information

Agency: Food and Drug Administration (FDA)
Event ID: 88806
Status: Resolved
Manufacturer: SUN PHARMACEUTICAL INDUSTRIES INC
Sold By: Major Pharmaceuticals; Ohm Laboratories Inc.
Manufactured In: United States
Units Affected: 2 products (22,752 blister packs; 46,584 blister packs)
Distributed To: Nationwide

AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.

Sources: FDA iRES · Raw API Response

openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.